FDA
-
-
-
-
-
-
-
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
-
-
-
-
-
-
-
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
-
-
-
-
-
-
-
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
-
-
-
-
-
-
-
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
-
-
-
-
-
-
-
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
-
327,804 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

